Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View expanded data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View expanded data table
# of AnimalsPhenotypeStrainSexValueUnitsConditionsRecord IDCondition 1aCondition 1bCondition 1cCondition 2aCondition 2bCondition 2cCondition 3aCondition 3bCondition 3c
217percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeN:HSboth41%myelin oligodendrocyte glycoprotein (50-120 ug) and Freund's complete adjuvant (100 ul) 66040myelin oligodendrocyte glycoprotein (50-120 ug) Freund's complete adjuvant (100 ul)
35mammary tumor numberWF.WKY-(D5Uwm67-D5Uwm98)/Uwmfemale3.27,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)702967,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
40mammary tumor numberWF.WKY-(D5Uwm76-D5Uwm61)/Uwmfemale4.27,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)702977,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
26mammary tumor numberWF.WKY-(D5Uwm76-D5Uwm98)/Uwmfemale3.87,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)702987,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
32mammary tumor numberWF.WKY-(D5Uwm67-D5Uwm78)/Uwmfemale8.67,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)702997,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
27mammary tumor numberWF.WKY-(D5Uwm76-D5Got18)/Uwmfemale3.57,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703007,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
32mammary tumor numberWF.WKY-(D5Uwm78-D5Uwm98)/Uwmfemale2.87,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703017,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
36mammary tumor numberWF.WKY-(D5Uwm95-D5Uwm98)/Uwmfemale7.47,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703027,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
26mammary tumor numberWF.WKY-(D5Uwm67-D5Uwm81)/Uwmfemale8.37,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703037,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
58mammary tumor numberWF.WKY-(D5Uwm76-D5Uwm92)/Uwmfemale4.87,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703047,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
29mammary tumor numberWF.WKY-(D5Uwm78-D5Uwm84)/Uwmfemale8.87,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703057,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
27mammary tumor numberWF.WKY-(D5Uwm78-D5Uwm93)/Uwmfemale57,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703067,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
41mammary tumor numberWF.WKY-(D5Uwm78-D5Uwm84)/Uwmfemale8.17,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703077,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
58mammary tumor numberWF.WKY-(D5Uwm88-D5Uwm92)/Uwmfemale6.97,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703087,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
56mammary tumor numberWF.WKY-(D5Uwm87-D5Uwm92)/Uwmfemale6.37,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703097,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
51mammary tumor numberWF.WKY-(D5Uwm85-D5Uwm92)/Uwmfemale3.97,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703107,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
18mammary tumor numberWF.WKY-(D5Uwm82-D5Uwm92)/Uwmfemale2.67,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703117,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
58mammary tumor numberWF.WKY-(D5Uwm82-D5Uwm91)/Uwmfemale3.47,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703127,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
12mammary tumor numberWF.WKY-(D5Uwm77-D5Uwm91)/Uwmfemale3.87,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703137,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
46mammary tumor numberWF/NHsdfemale7.97,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)703147,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
32mammary tumor numberWF.WKY-(D7Rat171-D7Rat128)/2Uwmfemale3.97,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660617,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
17mammary tumor numberWF.WKY-(D7Rat171-D7Rat128)/1Uwmfemale3.57,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660607,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
23mammary tumor numberWF.WKY-(D7Rat51-D7Rat128)/Uwmfemale87,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660627,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
43mammary tumor numberWF.WKY-(D7Uwm25-D7Rat128)/Uwmfemale7.27,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660637,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
28mammary tumor numberWF.WKY-(D7Rat171-D7Rat45)/Uwmfemale3.47,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660647,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
16mammary tumor numberWF.COP-(D7Rat39-D7Uwm12)/1Uwmfemale2.47,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660657,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
16mammary tumor numberWF.COP-(D7Rat39-D7Uwm12)/2Uwmfemale27,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660667,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
19mammary tumor numberWFfemale7.37,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)660677,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
7experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat12-D10Rat144)not specified14.4dmyelin oligodendrocyte glycoprotein (200 ul) 68221myelin oligodendrocyte glycoprotein (200 ul)
13percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat12-D10Rat144)not specified38.5%myelin oligodendrocyte glycoprotein (200 ul) 68222myelin oligodendrocyte glycoprotein (200 ul)
14experimental autoimmune encephalomyelitis durationDA/ZtmKininot specified18.5dmyelin oligodendrocyte glycoprotein (200 ul) 68224myelin oligodendrocyte glycoprotein (200 ul)
16percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified81.3%myelin oligodendrocyte glycoprotein (200 ul) 68225myelin oligodendrocyte glycoprotein (200 ul)
10experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat15-D10Rat29)not specified8.6dmyelin oligodendrocyte glycoprotein (200 ul) 68227myelin oligodendrocyte glycoprotein (200 ul)
13percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified30.8%myelin oligodendrocyte glycoprotein (200 ul) 68228myelin oligodendrocyte glycoprotein (200 ul)
13experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat219-D10Rat29)not specified7.4dmyelin oligodendrocyte glycoprotein (200 ul) 68230myelin oligodendrocyte glycoprotein (200 ul)
16percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat219-D10Rat29)not specified25%myelin oligodendrocyte glycoprotein (200 ul) 68231myelin oligodendrocyte glycoprotein (200 ul)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat219-D10Rat29)not specified60%myelin oligodendrocyte glycoprotein (200 ul) 67873myelin oligodendrocyte glycoprotein (200 ul)
16percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat219-D10Rat29)not specified81.2%myelin oligodendrocyte glycoprotein (200 ul) 67874myelin oligodendrocyte glycoprotein (200 ul)
7percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat10-D10Rat142)not specified85.7%myelin oligodendrocyte glycoprotein (200 ul) 67875myelin oligodendrocyte glycoprotein (200 ul)
13percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat12-D10Rat144)not specified53.8%myelin oligodendrocyte glycoprotein (200 ul) 67876myelin oligodendrocyte glycoprotein (200 ul)
1experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat2-D10Rat29)/Kininot specified3dmyelin oligodendrocyte glycoprotein (200 ul) 68730myelin oligodendrocyte glycoprotein (200 ul)
6experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat2-D10Rat29)/Kininot specified13.3dmyelin oligodendrocyte glycoprotein (200 ul) 68731myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kininot specified37.5%myelin oligodendrocyte glycoprotein (200 ul) 68732myelin oligodendrocyte glycoprotein (200 ul)
7percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kininot specified0%myelin oligodendrocyte glycoprotein (200 ul) 68733myelin oligodendrocyte glycoprotein (200 ul)
7percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kininot specified14.3%myelin oligodendrocyte glycoprotein (200 ul) 68734myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kininot specified75%myelin oligodendrocyte glycoprotein (200 ul) 68735myelin oligodendrocyte glycoprotein (200 ul)
12experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat15-D10Rat29)not specified3.5dmyelin oligodendrocyte glycoprotein (200 ul) 68194myelin oligodendrocyte glycoprotein (200 ul)
12percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified8.3%myelin oligodendrocyte glycoprotein (200 ul) 68195myelin oligodendrocyte glycoprotein (200 ul)
8experimental autoimmune encephalomyelitis durationDA/ZtmKininot specified13dmyelin oligodendrocyte glycoprotein (200 ul) 68197myelin oligodendrocyte glycoprotein (200 ul)
10percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified70%myelin oligodendrocyte glycoprotein (200 ul) 68198myelin oligodendrocyte glycoprotein (200 ul)
8experimental autoimmune encephalomyelitis durationDA/ZtmKininot specified16.4dmyelin oligodendrocyte glycoprotein (200 ul) 68200myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified87.5%myelin oligodendrocyte glycoprotein (200 ul) 68201myelin oligodendrocyte glycoprotein (200 ul)
5experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat15-D10Rat29)not specified13.4dmyelin oligodendrocyte glycoprotein (200 ul) 68203myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified37.5%myelin oligodendrocyte glycoprotein (200 ul) 68204myelin oligodendrocyte glycoprotein (200 ul)
8experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat2-D10Rat6)not specified18.9dmyelin oligodendrocyte glycoprotein (200 ul) 68206myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat6)not specified87.5%myelin oligodendrocyte glycoprotein (200 ul) 68207myelin oligodendrocyte glycoprotein (200 ul)
14experimental autoimmune encephalomyelitis durationDA/ZtmKininot specified13.4dmyelin oligodendrocyte glycoprotein (200 ul) 68209myelin oligodendrocyte glycoprotein (200 ul)
16percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified56.3%myelin oligodendrocyte glycoprotein (200 ul) 68210myelin oligodendrocyte glycoprotein (200 ul)
4experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat15-D10Rat29)not specified8.7dmyelin oligodendrocyte glycoprotein (200 ul) 68212myelin oligodendrocyte glycoprotein (200 ul)
10percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified30%myelin oligodendrocyte glycoprotein (200 ul) 68213myelin oligodendrocyte glycoprotein (200 ul)
6experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat219-D10Rat29)not specified11.5dmyelin oligodendrocyte glycoprotein (200 ul) 68215myelin oligodendrocyte glycoprotein (200 ul)
10percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat219-D10Rat29)not specified40%myelin oligodendrocyte glycoprotein (200 ul) 68216myelin oligodendrocyte glycoprotein (200 ul)
6experimental autoimmune encephalomyelitis durationDA.ACI-(D10Rat10-D10Rat142)not specified13.5dmyelin oligodendrocyte glycoprotein (200 ul) 68218myelin oligodendrocyte glycoprotein (200 ul)
7percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat10-D10Rat142)not specified71.4%myelin oligodendrocyte glycoprotein (200 ul) 68219myelin oligodendrocyte glycoprotein (200 ul)
12percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified33.3%myelin oligodendrocyte glycoprotein (200 ul) 67848myelin oligodendrocyte glycoprotein (200 ul)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified80%myelin oligodendrocyte glycoprotein (200 ul) 67849myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified100%myelin oligodendrocyte glycoprotein (200 ul) 67850myelin oligodendrocyte glycoprotein (200 ul)
16percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified87.5%myelin oligodendrocyte glycoprotein (200 ul) 67852myelin oligodendrocyte glycoprotein (200 ul)
16percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKininot specified87.5%myelin oligodendrocyte glycoprotein (200 ul) 67853myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified62.5%myelin oligodendrocyte glycoprotein (200 ul) 67855myelin oligodendrocyte glycoprotein (200 ul)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified40%myelin oligodendrocyte glycoprotein (200 ul) 67856myelin oligodendrocyte glycoprotein (200 ul)
13percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat15-D10Rat29)not specified76.9%myelin oligodendrocyte glycoprotein (200 ul) 67859myelin oligodendrocyte glycoprotein (200 ul)
8percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat6)not specified100%myelin oligodendrocyte glycoprotein (200 ul) 67860myelin oligodendrocyte glycoprotein (200 ul)
22percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale82%myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) 69487myelin oligodendrocyte glycoprotein (30 ug) Freund's incomplete adjuvant (100 ul)
21percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinimale76%myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) 69488myelin oligodendrocyte glycoprotein (30 ug) Freund's incomplete adjuvant (100 ul)
22experimental autoimmune encephalomyelitis durationDA/ZtmKinimale15.8dmyelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) 69489myelin oligodendrocyte glycoprotein (30 ug) Freund's incomplete adjuvant (100 ul)
21experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinimale11.7dmyelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) 69490myelin oligodendrocyte glycoprotein (30 ug) Freund's incomplete adjuvant (100 ul)
12post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale14.8dmyelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) 69491myelin oligodendrocyte glycoprotein (15-20 ug) Freund's incomplete adjuvant (100 ul)
13post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinifemale22.5dmyelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) 69492myelin oligodendrocyte glycoprotein (15-20 ug) Freund's incomplete adjuvant (100 ul)
22post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinimale19.6dmyelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) 69493myelin oligodendrocyte glycoprotein (30 ug) Freund's incomplete adjuvant (100 ul)
21post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinimale21.9dmyelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) 69494myelin oligodendrocyte glycoprotein (30 ug) Freund's incomplete adjuvant (100 ul)
N/Apercentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinifemale89%myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) 69497myelin oligodendrocyte glycoprotein (0.09 ug/g) Freund's incomplete adjuvant (100 ul)
N/Apercentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinifemale69%myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) 69498myelin oligodendrocyte glycoprotein (0.1 ug/g) Freund's incomplete adjuvant (100 ul)
N/Apost-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale15.6dmyelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) 69499myelin oligodendrocyte glycoprotein (0.09 ug/g) Freund's incomplete adjuvant (100 ul)
N/Apost-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinifemale22.5dmyelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) 69500myelin oligodendrocyte glycoprotein (0.1 ug/g) Freund's incomplete adjuvant (100 ul)
N/Aexperimental autoimmune encephalomyelitis durationDA/ZtmKinifemale20dmyelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) 69501myelin oligodendrocyte glycoprotein (0.09 ug/g) Freund's incomplete adjuvant (100 ul)
N/Aexperimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinifemale10.1dmyelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) 69502myelin oligodendrocyte glycoprotein (0.1 ug/g) Freund's incomplete adjuvant (100 ul)
12percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinifemale92%myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) 68122myelin oligodendrocyte glycoprotein (15-22 ug) Freund's incomplete adjuvant (100 ul)
13percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinifemale69%myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) 68123myelin oligodendrocyte glycoprotein (15-22 ug) Freund's incomplete adjuvant (100 ul)
12experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale19.7dmyelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) 69376myelin oligodendrocyte glycoprotein (15-20 ug) Freund's incomplete adjuvant (100 ul)
13experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D17Rat8-D17Rat37)/Kinifemale10.1dmyelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) 69377myelin oligodendrocyte glycoprotein (15-20 ug) Freund's incomplete adjuvant (100 ul)
20percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKiniboth60%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68124myelin oligodendrocyte glycoprotein (20 ug/200 ul)
19percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got126-D4Got136)both10%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68126myelin oligodendrocyte glycoprotein (20 ug/200 ul)
23percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKiniboth100%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68128myelin oligodendrocyte glycoprotein (20 ug/200 ul)
21percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got126-D4Got136)both100%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68130myelin oligodendrocyte glycoprotein (20 ug/200 ul)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale80%myelin oligodendrocyte glycoprotein (20 ug) 68706myelin oligodendrocyte glycoprotein (20 ug)
8post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinimale16.2dmyelin oligodendrocyte glycoprotein (20 ug) 68707myelin oligodendrocyte glycoprotein (20 ug)
8percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale87.5%myelin oligodendrocyte glycoprotein (20 ug) 68709myelin oligodendrocyte glycoprotein (20 ug)
12percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale50%myelin oligodendrocyte glycoprotein (20 ug) 68710myelin oligodendrocyte glycoprotein (20 ug)
6post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinimale21.2dmyelin oligodendrocyte glycoprotein (20 ug) 68711myelin oligodendrocyte glycoprotein (20 ug)
6percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale50%myelin oligodendrocyte glycoprotein (20 ug) 68713myelin oligodendrocyte glycoprotein (20 ug)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale80%myelin oligodendrocyte glycoprotein (20 ug) 68714myelin oligodendrocyte glycoprotein (20 ug)
8post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinimale19.2dmyelin oligodendrocyte glycoprotein (20 ug) 68715myelin oligodendrocyte glycoprotein (20 ug)
8percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale87.5%myelin oligodendrocyte glycoprotein (20 ug) 68717myelin oligodendrocyte glycoprotein (20 ug)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kinimale30%myelin oligodendrocyte glycoprotein (20 ug) 68718myelin oligodendrocyte glycoprotein (20 ug)
3post-insult time to onset of experimental autoimmune encephalomyelitisDA.ACI-(D10Rat2-D10Rat29)/Kinimale14.7dmyelin oligodendrocyte glycoprotein (20 ug) 68719myelin oligodendrocyte glycoprotein (20 ug)
3percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kinimale0%myelin oligodendrocyte glycoprotein (20 ug) 68721myelin oligodendrocyte glycoprotein (20 ug)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kinimale0%myelin oligodendrocyte glycoprotein (20 ug) 68722myelin oligodendrocyte glycoprotein (20 ug)
8percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kinimale0%myelin oligodendrocyte glycoprotein (20 ug) 68724myelin oligodendrocyte glycoprotein (20 ug)
7percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kinimale14%myelin oligodendrocyte glycoprotein (20 ug) 68726myelin oligodendrocyte glycoprotein (20 ug)
1post-insult time to onset of experimental autoimmune encephalomyelitisDA.ACI-(D10Rat2-D10Rat29)/Kinimale23dmyelin oligodendrocyte glycoprotein (20 ug) 68727myelin oligodendrocyte glycoprotein (20 ug)
1percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA.ACI-(D10Rat2-D10Rat29)/Kinimale0%myelin oligodendrocyte glycoprotein (20 ug) 68729myelin oligodendrocyte glycoprotein (20 ug)
11percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale100%myelin oligodendrocyte glycoprotein (20 ug) 68132myelin oligodendrocyte glycoprotein (20 ug)
11post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinimale14.9dmyelin oligodendrocyte glycoprotein (20 ug) 68133myelin oligodendrocyte glycoprotein (20 ug)
11percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinimale91%myelin oligodendrocyte glycoprotein (20 ug) 68135myelin oligodendrocyte glycoprotein (20 ug)
105percentage of study population developing experimental arthritis during a period of timeDA/Bklboth100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 69959type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
13percentage of study population developing experimental arthritis during a period of timeBN/SsNboth0%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 69961type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
105post-insult time to onset of experimental arthritisDA/Bklboth15dtype II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 68143type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
28percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinifemale64%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days)69378myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days)
24percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale33%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69379myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
28post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale26.5dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days)69380myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days)
28experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale10.7dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days)69381myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days)
24post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale33dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69382myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
24experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale5.5dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69383myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
16percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinifemale50%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69384myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
16post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale33.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69385myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
16experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale6.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69386myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
16percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got211-D4Mit12)/Kinifemale38%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69387myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
16post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Got211-D4Mit12)/Kinifemale33.9dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69388myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
16experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Got211-D4Mit12)/Kinifemale4.9dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69389myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
18percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinifemale94%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69390myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
18post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale16.7dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69391myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
18experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale14.3dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69392myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
18experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale20.9dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69393myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale90%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69394myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
10post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale18.2dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69395myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
10experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale22.6dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69396myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
19percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got211-D4Mit12)/Kinifemale100%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69397myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
19post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Got211-D4Mit12)/Kinifemale15.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69398myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
19experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Got211-D4Mit12)/Kinifemale11.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)69399myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days)
11percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale91%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69406myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
11post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale17.4dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69407myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
11experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale17.6dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)69408myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/ZtmKinifemale100%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69409myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
10post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale14.1dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69410myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
10experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale23.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69411myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
7percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale100%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69412myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
7post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale16.3dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69413myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
7experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale22.4dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69414myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
14percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Rat23-D4Mit12)/Kinifemale86%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69415myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
14post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat23-D4Mit12)/Kinifemale11.2dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69416myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
14experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat23-D4Mit12)/Kinifemale18.4dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)69417myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days)
21post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale18.7dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)69418myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)
21experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale11.5dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)69419myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)
19post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat103-D4Mit12)/Kinifemale17.3dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)69420myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)
19experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat103-D4Mit12)/Kinifemale11.2dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)69421myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)
21post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat231-D4Mit12)/Kinifemale16.2dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)69422myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)
21experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat231-D4Mit12)/Kinifemale13.3dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)69423myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days)
17post-insult time to onset of experimental autoimmune encephalomyelitisDA/ZtmKinifemale25.2dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69424myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
17experimental autoimmune encephalomyelitis durationDA/ZtmKinifemale9dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69425myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
10percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale30%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69426myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
10post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale32.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69427myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
10experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat23-D4Rat108)/Kinifemale2.7dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69428myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
18post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat23-D4Mit12)/Kinifemale31.2dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69429myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
18experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat23-D4Mit12)/Kinifemale6dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69430myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
9post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat103-D4Mit12)/Kinifemale28.4dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69431myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
9experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat103-D4Mit12)/Kinifemale5.9dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69432myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
14post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Rat231-D4Mit12)/Kinifemale28.9dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69433myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
14experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Rat231-D4Mit12)/Kinifemale7.8dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69434myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
6percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale50%myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69435myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
6post-insult time to onset of experimental autoimmune encephalomyelitisDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale28.3dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69436myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
6experimental autoimmune encephalomyelitis durationDA.PVG.1AV1-(D4Got60-D4Kini1)/Kinifemale7.5dmyelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)69437myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)
9litter sizeSHR/OlaIpcvmale7.6control condition69023control condition
9litter sizeBN-Lx/Cubmale4.5control condition69024control condition
9experimental autoimmune encephalomyelitis durationDA/Ztmmale9dspinal cord homogenate (10 mg) 69953spinal cord homogenate (10 mg)
3percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeE3/Ztmmale0%spinal cord homogenate (10 mg) 69954spinal cord homogenate (10 mg)
12percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeE3/Ztmfemale0%spinal cord homogenate (10 mg) 69955spinal cord homogenate (10 mg)
9percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/Ztmmale78%spinal cord homogenate (10 mg) 69949spinal cord homogenate (10 mg)
9percentage of study population developing acute experimental autoimmune encephalomyelitis during a period of timeDA/Ztmmale22%spinal cord homogenate (10 mg) 69950spinal cord homogenate (10 mg)
9percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of timeDA/Ztmmale56%spinal cord homogenate (10 mg) 69951spinal cord homogenate (10 mg)
9post-insult time to onset of experimental autoimmune encephalomyelitisDA/Ztmmale13dspinal cord homogenate (10 mg) 69952spinal cord homogenate (10 mg)
70percentage of study population developing cataract during a period of timeIER/Ihrfemale100%control condition69906control condition
73percentage of study population developing cataract during a period of timeIER/Ihrmale100%control condition69907control condition
11percentage of study population developing experimental arthritis during a period of timeLEW/Hanboth82%pristane (150 ul) 69660pristane (150 ul)
10percentage of study population developing experimental arthritis during a period of timeLEW.1Fboth100%pristane (150 ul) 69661pristane (150 ul)
11percentage of study population developing experimental arthritis during a period of timeLEW.1Nboth64%pristane (150 ul) 69662pristane (150 ul)
17percentage of study population developing experimental arthritis during a period of timeDA/ZtmRhdboth100%pristane (150 ul) 69663pristane (150 ul)
23percentage of study population developing experimental arthritis during a period of timeE3/ZtmRhdboth9%pristane (150 ul) 69664pristane (150 ul)
20percentage of study population developing experimental arthritis during a period of timeDXE1/Ztmboth70%pristane (150 ul) 69665pristane (150 ul)
24percentage of study population developing experimental arthritis during a period of timeDXE2/Ztmboth33%pristane (150 ul) 69666pristane (150 ul)
20percentage of study population developing experimental arthritis during a period of timeDXE3/Ztmboth10%pristane (150 ul) 69667pristane (150 ul)
11post-insult time to onset of experimental arthritisLEW/Hanboth23dpristane (150 ul) 69668pristane (150 ul)
10post-insult time to onset of experimental arthritisLEW.1Fboth17dpristane (150 ul) 69669pristane (150 ul)
11post-insult time to onset of experimental arthritisLEW.1Nboth21dpristane (150 ul) 69670pristane (150 ul)
17post-insult time to onset of experimental arthritisDA/ZtmRhdboth14dpristane (150 ul) 69671pristane (150 ul)
23post-insult time to onset of experimental arthritisE3/ZtmRhdboth38dpristane (150 ul) 69672pristane (150 ul)
20post-insult time to onset of experimental arthritisDXE1/Ztmboth31dpristane (150 ul) 69673pristane (150 ul)
24post-insult time to onset of experimental arthritisDXE2/Ztmboth72dpristane (150 ul) 69674pristane (150 ul)
20post-insult time to onset of experimental arthritisDXE3/Ztmboth32dpristane (150 ul) 69675pristane (150 ul)
11percentage of study population developing chronic experimental arthritis during a period of timeLEW/Hanboth82%pristane (150 ul) 69676pristane (150 ul)
10percentage of study population developing chronic experimental arthritis during a period of timeLEW.1Fboth100%pristane (150 ul) 69677pristane (150 ul)
11percentage of study population developing chronic experimental arthritis during a period of timeLEW.1Nboth54%pristane (150 ul) 69678pristane (150 ul)
17percentage of study population developing chronic experimental arthritis during a period of timeDA/ZtmRhdboth100%pristane (150 ul) 69679pristane (150 ul)
23percentage of study population developing chronic experimental arthritis during a period of timeE3/ZtmRhdboth0%pristane (150 ul) 69680pristane (150 ul)
20percentage of study population developing experimental arthritis during a period of timeDXE1/Ztmboth10%pristane (150 ul) 69681pristane (150 ul)
24percentage of study population developing chronic experimental arthritis during a period of timeDXE2/Ztmboth30%pristane (150 ul) 69682pristane (150 ul)
20percentage of study population developing chronic experimental arthritis during a period of timeDXE3/Ztmboth0%pristane (150 ul) 69683pristane (150 ul)
18gestation period lengthHanTac:WHfemale23dvehicle control condition (for 14 days)96583vehicle control condition (for 14 days)
21gestation period lengthHanTac:WHfemale22.9dbisphenol A (0.025 mg/kg/d) (for 14 days)96584bisphenol A (0.025 mg/kg/d) (for 14 days)
18gestation period lengthHanTac:WHfemale22.9dbisphenol A (5 mg/kg/d) (for 14 days)96585bisphenol A (5 mg/kg/d) (for 14 days)
17gestation period lengthHanTac:WHfemale22.9dbisphenol A (0.25 mg/kg/d) (for 14 days)96582bisphenol A (0.25 mg/kg/d) (for 14 days)
18gestation period lengthHanTac:WHfemale23dbisphenol A (50 mg/kg/d) (for 14 days)96586bisphenol A (50 mg/kg/d) (for 14 days)
17areola mammae/nipple numberHanTac:WHmale0.1vehicle control condition (for 14 days)96627vehicle control condition (for 14 days)
17areola mammae/nipple numberHanTac:WHmale0.2bisphenol A (0.025 mg/kg/d) (for 14 days)96628bisphenol A (0.025 mg/kg/d) (for 14 days)
17areola mammae/nipple numberHanTac:WHmale0.2bisphenol A (0.25 mg/kg/d) (for 14 days)96629bisphenol A (0.25 mg/kg/d) (for 14 days)
17areola mammae/nipple numberHanTac:WHmale0.3bisphenol A (5 mg/kg/d) (for 14 days)96630bisphenol A (5 mg/kg/d) (for 14 days)
17areola mammae/nipple numberHanTac:WHmale0.4bisphenol A (50 mg/kg/d) (for 14 days)96631bisphenol A (50 mg/kg/d) (for 14 days)
18number of fetuses lost perinatally to litter size ratioHanTac:WHfemale8.5%vehicle control condition (for 14 days)96592vehicle control condition (for 14 days)
21number of fetuses lost perinatally to litter size ratioHanTac:WHfemale10.8%bisphenol A (0.025 mg/kg/d) (for 14 days)96593bisphenol A (0.025 mg/kg/d) (for 14 days)
17number of fetuses lost perinatally to litter size ratioHanTac:WHfemale9.2%bisphenol A (0.25 mg/kg/d) (for 14 days)96594bisphenol A (0.25 mg/kg/d) (for 14 days)
18number of fetuses lost perinatally to litter size ratioHanTac:WHfemale6.8%bisphenol A (5 mg/kg/d) (for 14 days)96595bisphenol A (5 mg/kg/d) (for 14 days)
18number of fetuses lost perinatally to litter size ratioHanTac:WHfemale17.9%bisphenol A (50 mg/kg/d) (for 14 days)96596bisphenol A (50 mg/kg/d) (for 14 days)
17number of male offspring to litter size ratioHanTac:WHfemale45.1%bisphenol A (0.25 mg/kg/d) (for 14 days)96609bisphenol A (0.25 mg/kg/d) (for 14 days)
18litter sizeHanTac:WHfemale11.8vehicle control condition (for 14 days)96597vehicle control condition (for 14 days)
21litter sizeHanTac:WHfemale11.7bisphenol A (0.025 mg/kg/d) (for 14 days)96598bisphenol A (0.025 mg/kg/d) (for 14 days)
17litter sizeHanTac:WHfemale12.1bisphenol A (0.25 mg/kg/d) (for 14 days)96599bisphenol A (0.25 mg/kg/d) (for 14 days)
18litter sizeHanTac:WHfemale11.4bisphenol A (5 mg/kg/d) (for 14 days)96600bisphenol A (5 mg/kg/d) (for 14 days)
18litter sizeHanTac:WHfemale11.2bisphenol A (50 mg/kg/d) (for 14 days)96601bisphenol A (50 mg/kg/d) (for 14 days)
18number of male offspring to litter size ratioHanTac:WHfemale50.5%vehicle control condition (for 14 days)96607vehicle control condition (for 14 days)
21number of male offspring to litter size ratioHanTac:WHfemale49.8%bisphenol A (0.025 mg/kg/d) (for 14 days)96608bisphenol A (0.025 mg/kg/d) (for 14 days)
18number of male offspring to litter size ratioHanTac:WHfemale49.7%bisphenol A (5 mg/kg/d) (for 14 days)96610bisphenol A (5 mg/kg/d) (for 14 days)
18number of male offspring to litter size ratioHanTac:WHfemale56.2%bisphenol A (50 mg/kg/d) (for 14 days)96611bisphenol A (50 mg/kg/d) (for 14 days)
18number of perinatal live-born offspring deaths to litter size ratioHanTac:WHfemale3.2%vehicle control condition (for 14 days)96602vehicle control condition (for 14 days)
21number of perinatal live-born offspring deaths to litter size ratioHanTac:WHfemale3.3%bisphenol A (0.025 mg/kg/d) (for 14 days)96603bisphenol A (0.025 mg/kg/d) (for 14 days)
17number of perinatal live-born offspring deaths to litter size ratioHanTac:WHfemale2.5%bisphenol A (0.25 mg/kg/d) (for 14 days)96604bisphenol A (0.25 mg/kg/d) (for 14 days)
18number of perinatal live-born offspring deaths to litter size ratioHanTac:WHfemale1%bisphenol A (5 mg/kg/d) (for 14 days)96605bisphenol A (5 mg/kg/d) (for 14 days)
18number of perinatal live-born offspring deaths to litter size ratioHanTac:WHfemale8.6%bisphenol A (50 mg/kg/d) (for 14 days)96606bisphenol A (50 mg/kg/d) (for 14 days)
13percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiruboth15.4%Freund's incomplete adjuvant (200 ul) 70193Freund's incomplete adjuvant (200 ul)
27post-insult time to onset of experimental arthritisDA/ZtmKiniboth14dFreund's incomplete adjuvant (200 ul) 70194Freund's incomplete adjuvant (200 ul)
30post-insult time to onset of experimental arthritisDA.PVG-(D4Rat141-D4Mgh11)both31.7dFreund's incomplete adjuvant (200 ul) 70195Freund's incomplete adjuvant (200 ul)
5post-insult time to onset of experimental arthritisDA/ZtmKiniboth12.2dFreund's incomplete adjuvant (200 ul) 70196Freund's incomplete adjuvant (200 ul)
12percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-Spr)both25%Freund's incomplete adjuvant (200 ul) 70197Freund's incomplete adjuvant (200 ul)
12post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-Spr)both13.7dFreund's incomplete adjuvant (200 ul) 70198Freund's incomplete adjuvant (200 ul)
7percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Mgh17-D4Rat56)both100%Freund's incomplete adjuvant (200 ul) 70199Freund's incomplete adjuvant (200 ul)
7post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Mgh17-D4Rat56)both12.4dFreund's incomplete adjuvant (200 ul) 70200Freund's incomplete adjuvant (200 ul)
37percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat63-D4Rat203)both5%Freund's incomplete adjuvant (200 ul) 70201Freund's incomplete adjuvant (200 ul)
37post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat63-D4Rat203)both14dFreund's incomplete adjuvant (200 ul) 70202Freund's incomplete adjuvant (200 ul)
27percentage of study population developing experimental arthritis during a period of timeDA/ZtmKiniboth96.3%Freund's incomplete adjuvant (200 ul) 70188Freund's incomplete adjuvant (200 ul)
12percentage of study population developing experimental arthritis during a period of timeLEW.1AV1/Kiniboth0%Freund's incomplete adjuvant (200 ul) 70189Freund's incomplete adjuvant (200 ul)
29percentage of study population developing experimental arthritis during a period of timePVG.1AV1/Kiniboth0%Freund's incomplete adjuvant (200 ul) 70190Freund's incomplete adjuvant (200 ul)
30percentage of study population developing experimental arthritis during a period of timeDA.PVG-(D4Rat141-D4Mgh11)both10%Freund's incomplete adjuvant (200 ul) 70191Freund's incomplete adjuvant (200 ul)
5percentage of study population developing experimental arthritis during a period of timeDA/ZtmKiniboth100%Freund's incomplete adjuvant (200 ul) 70192Freund's incomplete adjuvant (200 ul)
11percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiruboth45%Freund's incomplete adjuvant (200 ul) 84878Freund's incomplete adjuvant (200 ul)
10percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiruboth100%Freund's incomplete adjuvant (200 ul) 84879Freund's incomplete adjuvant (200 ul)
11post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat231-D4Mit12)/Kiniboth13.3dFreund's incomplete adjuvant (200 ul) 84922Freund's incomplete adjuvant (200 ul)
8post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiruboth14.4dFreund's incomplete adjuvant (200 ul) 84923Freund's incomplete adjuvant (200 ul)
14post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Got126-D4Got136)both19dFreund's incomplete adjuvant (200 ul) 84924Freund's incomplete adjuvant (200 ul)
11post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiruboth17.2dFreund's incomplete adjuvant (200 ul) 84925Freund's incomplete adjuvant (200 ul)
18post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiruboth14.8dFreund's incomplete adjuvant (200 ul) 84926Freund's incomplete adjuvant (200 ul)
16percentage of study population developing experimental arthritis during a period of timePVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiruboth68.8%Freund's incomplete adjuvant (200 ul) 84872Freund's incomplete adjuvant (200 ul)
14percentage of study population developing experimental arthritis during a period of timeDA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiruboth0%Freund's incomplete adjuvant (200 ul) 84873Freund's incomplete adjuvant (200 ul)
7percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-D4Rat84)both0%Freund's incomplete adjuvant (200 ul) 84874Freund's incomplete adjuvant (200 ul)
9percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiruboth100%Freund's incomplete adjuvant (200 ul) 84875Freund's incomplete adjuvant (200 ul)
9percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiruboth22%Freund's incomplete adjuvant (200 ul) 84876Freund's incomplete adjuvant (200 ul)
11percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat203-D4Got130)/Kiruboth100%Freund's incomplete adjuvant (200 ul) 84877Freund's incomplete adjuvant (200 ul)
12percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiruboth100%Freund's incomplete adjuvant (200 ul) 84880Freund's incomplete adjuvant (200 ul)
7percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Got126-D4Rat203)/Kiruboth43%Freund's incomplete adjuvant (200 ul) 84881Freund's incomplete adjuvant (200 ul)
9post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiruboth17dFreund's incomplete adjuvant (200 ul) 84900Freund's incomplete adjuvant (200 ul)
13post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiruboth16dFreund's incomplete adjuvant (200 ul) 84903Freund's incomplete adjuvant (200 ul)
16post-insult time to onset of experimental arthritisPVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiruboth20.2dFreund's incomplete adjuvant (200 ul) 84910Freund's incomplete adjuvant (200 ul)
9post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiruboth14.4dFreund's incomplete adjuvant (200 ul) 84915Freund's incomplete adjuvant (200 ul)
11post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat203-D4Got130)/Kiruboth14.9dFreund's incomplete adjuvant (200 ul) 84916Freund's incomplete adjuvant (200 ul)
11post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiruboth14dFreund's incomplete adjuvant (200 ul) 84917Freund's incomplete adjuvant (200 ul)
10post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiruboth12.6dFreund's incomplete adjuvant (200 ul) 84918Freund's incomplete adjuvant (200 ul)
12post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiruboth13dFreund's incomplete adjuvant (200 ul) 84919Freund's incomplete adjuvant (200 ul)
7post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Got126-D4Rat203)/Kiruboth12.7dFreund's incomplete adjuvant (200 ul) 84920Freund's incomplete adjuvant (200 ul)
12post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat62-D4Got136)/Kiruboth15.4dFreund's incomplete adjuvant (200 ul) 84921Freund's incomplete adjuvant (200 ul)
12percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat62-D4Got136)/Kiruboth75%Freund's incomplete adjuvant (200 ul) 84882Freund's incomplete adjuvant (200 ul)
11percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat231-D4Mit12)/Kiniboth100%Freund's incomplete adjuvant (200 ul) 84883Freund's incomplete adjuvant (200 ul)
8percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiruboth100%Freund's incomplete adjuvant (200 ul) 84884Freund's incomplete adjuvant (200 ul)
14percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Got126-D4Got136)both64%Freund's incomplete adjuvant (200 ul) 84886Freund's incomplete adjuvant (200 ul)
11percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiruboth55%Freund's incomplete adjuvant (200 ul) 84889Freund's incomplete adjuvant (200 ul)
18percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiruboth89%Freund's incomplete adjuvant (200 ul) 84892Freund's incomplete adjuvant (200 ul)
24percentage of study population developing experimental arthritis during a period of timeDA/ZtmKinimale100%Freund's incomplete adjuvant (200 ul) 84465Freund's incomplete adjuvant (200 ul)
24percentage of study population developing experimental arthritis during a period of timeDA/ZtmKinifemale91.7%Freund's incomplete adjuvant (200 ul) 84466Freund's incomplete adjuvant (200 ul)
24post-insult time to onset of experimental arthritisDA/ZtmKinimale14.6dFreund's incomplete adjuvant (200 ul) 84467Freund's incomplete adjuvant (200 ul)
24post-insult time to onset of experimental arthritisDA/ZtmKinifemale14.6dFreund's incomplete adjuvant (200 ul) 84468Freund's incomplete adjuvant (200 ul)
15percentage of study population developing experimental arthritis during a period of timeDA/ZtmKiniboth93%Freund's incomplete adjuvant (200 ul) 84469Freund's incomplete adjuvant (200 ul)
6percentage of study population developing experimental arthritis during a period of timeDA/ZtmKiniboth100%Freund's incomplete adjuvant (200 ul) 84470Freund's incomplete adjuvant (200 ul)
15post-insult time to onset of experimental arthritisDA/ZtmKiniboth14.9dFreund's incomplete adjuvant (200 ul) 84471Freund's incomplete adjuvant (200 ul)
6post-insult time to onset of experimental arthritisDA/ZtmKiniboth16.3dFreund's incomplete adjuvant (200 ul) 84472Freund's incomplete adjuvant (200 ul)
10percentage of study population developing experimental arthritis during a period of timeDA/Bklmale50%Freund's incomplete adjuvant (0.1 ml) 69551Freund's incomplete adjuvant (0.1 ml)
12percentage of study population developing experimental arthritis during a period of timeDA/Bklmale83.3%Freund's incomplete adjuvant (0.1 ml) 69552Freund's incomplete adjuvant (0.1 ml)
12post-insult time to onset of experimental arthritisDA/Bklmale15.8dFreund's incomplete adjuvant (0.1 ml) 69553Freund's incomplete adjuvant (0.1 ml)
10post-insult time to onset of experimental arthritisDA/Bklmale14.4dFreund's incomplete adjuvant (0.1 ml) 69554Freund's incomplete adjuvant (0.1 ml)
6percentage of study population developing experimental arthritis during a period of timeLEW/NHsdnot specified0%Freund's incomplete adjuvant (0.1 ml) 97068Freund's incomplete adjuvant (0.1 ml)
6percentage of study population developing experimental arthritis during a period of timeLEW/NHsdnot specified0%0.9% sodium chloride solution (0.1 ml) 970690.9% sodium chloride solution (0.1 ml)
10percentage of study population developing experimental arthritis during a period of timeDA/Bklmale0%0.9% sodium chloride solution (0.1 ml) 970700.9% sodium chloride solution (0.1 ml)
12percentage of study population developing experimental arthritis during a period of timeDA/Bklmale0%0.9% sodium chloride solution (0.1 ml) 970710.9% sodium chloride solution (0.1 ml)
9percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeBNnot specified0%central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) 69967central nervous system myelin (5 mg/ml) Freund's complete adjuvant (50 %)
9percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLEWnot specified100%central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) 69968central nervous system myelin (5 mg/ml) Freund's complete adjuvant (50 %)
36percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeDA/Ztmnot specified72%myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) 69969myelin oligodendrocyte glycoprotein (0.25 mg/ml) Freund's incomplete adjuvant (50 %)
21percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeACI/SegHsdnot specified5%myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) 69970myelin oligodendrocyte glycoprotein (0.25 mg/ml) Freund's incomplete adjuvant (50 %)
10percentage of study population developing experimental arthritis during a period of timeDA/ZtmRhdboth100%pristane (150 ul) 70128pristane (150 ul)
11percentage of study population developing experimental arthritis during a period of timeLEW.1Fboth100%pristane (150 ul) 70129pristane (150 ul)
10percentage of study population developing experimental arthritis during a period of timeE3both0%pristane (150 ul) 70130pristane (150 ul)
10post-insult time to onset of experimental arthritisDA/ZtmRhdboth14dpristane (150 ul) 70131pristane (150 ul)
10post-insult time to onset of experimental arthritisE3both0dpristane (150 ul) 70132pristane (150 ul)
11post-insult time to onset of experimental arthritisLEW.1Fboth17dpristane (150 ul) 70133pristane (150 ul)
10subjects with ankylosis to total subjects with arthritis ratioDA/ZtmRhdboth75%pristane (150 ul) 70134pristane (150 ul)
11subjects with ankylosis to total subjects with arthritis ratioLEW.1Fboth0%pristane (150 ul) 70135pristane (150 ul)
10subjects with ankylosis to total subjects with arthritis ratioE3both0%pristane (150 ul) 70136pristane (150 ul)
10arthritic paw countDA/ZtmRhdboth3.7pristane (150 ul) 70137pristane (150 ul)
11arthritic paw countLEW.1Fboth3.4pristane (150 ul) 70138pristane (150 ul)
10arthritic paw countE3both0pristane (150 ul) 70139pristane (150 ul)
8percentage of study population developing experimental arthritis during a period of timeDA/Ztmfemale100%squalene (860 mg/ml) 69624squalene (860 mg/ml)
6percentage of study population developing experimental arthritis during a period of timeDA/Ztmmale100%squalene (860 mg/ml) 69625squalene (860 mg/ml)
15percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubcfemale73%squalene (860 mg/ml) 69626squalene (860 mg/ml)
13percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubcmale85%squalene (860 mg/ml) 69627squalene (860 mg/ml)
14percentage of study population developing experimental arthritis during a period of timeLEW.1AV1female14%squalene (860 mg/ml) 69628squalene (860 mg/ml)
9percentage of study population developing experimental arthritis during a period of timeLEW.1AV1male11%squalene (860 mg/ml) 69629squalene (860 mg/ml)
8subjects with ankylosis to total subjects with arthritis ratioDA/Ztmfemale38%squalene (860 mg/ml) 69630squalene (860 mg/ml)
6subjects with ankylosis to total subjects with arthritis ratioDA/Ztmmale50%squalene (860 mg/ml) 69631squalene (860 mg/ml)
11subjects with ankylosis to total subjects with arthritis ratioLEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubcfemale18%squalene (860 mg/ml) 69632squalene (860 mg/ml)
11subjects with ankylosis to total subjects with arthritis ratioLEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubcmale36%squalene (860 mg/ml) 69633squalene (860 mg/ml)
2subjects with ankylosis to total subjects with arthritis ratioLEW.1AV1female0%squalene (860 mg/ml) 69634squalene (860 mg/ml)
1subjects with ankylosis to total subjects with arthritis ratioLEW.1AV1male0%squalene (860 mg/ml) 69635squalene (860 mg/ml)
8post-insult time to onset of experimental arthritisDA/Ztmfemale14dsqualene (860 mg/ml) 69636squalene (860 mg/ml)
6post-insult time to onset of experimental arthritisDA/Ztmmale14dsqualene (860 mg/ml) 69637squalene (860 mg/ml)
11post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubcfemale18dsqualene (860 mg/ml) 69638squalene (860 mg/ml)
11post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubcmale18dsqualene (860 mg/ml) 69639squalene (860 mg/ml)
2post-insult time to onset of experimental arthritisLEW.1AV1female18dsqualene (860 mg/ml) 69640squalene (860 mg/ml)
1post-insult time to onset of experimental arthritisLEW.1AV1male22dsqualene (860 mg/ml) 69641squalene (860 mg/ml)
17percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubcfemale29%squalene (860 mg/ml) 69642squalene (860 mg/ml)
6percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubcmale33%squalene (860 mg/ml) 69643squalene (860 mg/ml)
13percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubcfemale77%squalene (860 mg/ml) 69644squalene (860 mg/ml)
17percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubcmale71%squalene (860 mg/ml) 69645squalene (860 mg/ml)
26percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Got154-D10Rat135)/Ubcfemale69%squalene (860 mg/ml) 69646squalene (860 mg/ml)
28percentage of study population developing experimental arthritis during a period of timeLEW.1AV1.DA-(D10Got154-D10Rat135)/Ubcmale50%squalene (860 mg/ml) 69647squalene (860 mg/ml)
17post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubcfemale24dsqualene (860 mg/ml) 69648squalene (860 mg/ml)
6post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubcmale22dsqualene (860 mg/ml) 69649squalene (860 mg/ml)
13post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubcfemale22dsqualene (860 mg/ml) 69650squalene (860 mg/ml)
17post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubcmale24dsqualene (860 mg/ml) 69651squalene (860 mg/ml)
26post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Got154-D10Rat135)/Ubcfemale22dsqualene (860 mg/ml) 69652squalene (860 mg/ml)
28post-insult time to onset of experimental arthritisLEW.1AV1.DA-(D10Got154-D10Rat135)/Ubcmale24dsqualene (860 mg/ml) 69653squalene (860 mg/ml)
30percentage of study population developing experimental arthritis during a period of timeDA/ZtmRhdboth93%pristane (150 ul) (for 56 days)69591pristane (150 ul) (for 56 days)
25percentage of study population developing experimental arthritis during a period of timeE3/ZtmRhdboth0%pristane (150 ul) (for 56 days)69592pristane (150 ul) (for 56 days)
30post-insult time to onset of experimental arthritisDA/ZtmRhdboth14dpristane (150 ul) (for 56 days)69593pristane (150 ul) (for 56 days)
30percentage of study population developing chronic experimental arthritis during a period of timeDA/ZtmRhdboth87%pristane (150 ul) (for 120 days)69595pristane (150 ul) (for 120 days)
25percentage of study population developing chronic experimental arthritis during a period of timeE3/ZtmRhdboth0%pristane (150 ul) (for 120 days)69966pristane (150 ul) (for 120 days)
17percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth100%pristane (150 ul) 69716pristane (150 ul)
18percentage of study population developing experimental arthritis during a period of timePVG.1AV1both33%pristane (150 ul) 69717pristane (150 ul)
16percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-D4Rat84)both69%pristane (150 ul) 69718pristane (150 ul)
24percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-Spr)both100%pristane (150 ul) 69719pristane (150 ul)
9percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth100%squalene (200 ul) 69720squalene (200 ul)
10percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat63-D4Rat203)both100%squalene (200 ul) 69721squalene (200 ul)
10percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69722type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
10percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat63-D4Rat203)both100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69723type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
10percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth100%pristane (150 ul) 69724pristane (150 ul)
10percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat63-D4Rat203)both90%pristane (150 ul) 69725pristane (150 ul)
15post-insult time to onset of experimental arthritisDA/Ztmboth13dsqualene (200 ul) 69773squalene (200 ul)
11post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-D4Rat84)both16dsqualene (200 ul) 69774squalene (200 ul)
16post-insult time to onset of experimental arthritisDA/Ztmboth14.9dFreund's complete adjuvant (100 ul) 69775Freund's complete adjuvant (100 ul)
14post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-D4Rat84)both13.6dFreund's complete adjuvant (100 ul) 69776Freund's complete adjuvant (100 ul)
12post-insult time to onset of experimental arthritisDA/Ztmboth14.5dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69777type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
15percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth100%squalene (200 ul) 69703squalene (200 ul)
10percentage of study population developing experimental arthritis during a period of timePVG.1AV1both0%squalene (200 ul) 69704squalene (200 ul)
11percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-D4Rat84)both73%squalene (200 ul) 69705squalene (200 ul)
16percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth88%Freund's complete adjuvant (100 ul) 69706Freund's complete adjuvant (100 ul)
15percentage of study population developing experimental arthritis during a period of timePVG.1AV1both0%Freund's complete adjuvant (100 ul) 69707Freund's complete adjuvant (100 ul)
14percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-D4Rat84)both36%Freund's complete adjuvant (100 ul) 69708Freund's complete adjuvant (100 ul)
12percentage of study population developing experimental arthritis during a period of timeDA/Ztmboth100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69709type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
15percentage of study population developing experimental arthritis during a period of timePVG.1AV1both33%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69710type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
14percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-D4Rat84)both71%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69711type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
14percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Rat155-Spr)both100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69712type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
11percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Mgh17-D4Rat56)both100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69713type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
9percentage of study population developing experimental arthritis during a period of timeDA/Ztmmale100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69714type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
13percentage of study population developing experimental arthritis during a period of timeDA.PVG.1AV1-(D4Mgh17-D4Rat56)male100%type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69715type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
15post-insult time to onset of experimental arthritisPVG.1AV1both14.6dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69778type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
14post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-D4Rat84)both17.6dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69779type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
14post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-Spr)both14.3dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69780type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
11post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Mgh17-D4Rat56)both15.4dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69781type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
13post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Mgh17-D4Rat56)male15.5dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69783type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
17post-insult time to onset of experimental arthritisDA/Ztmboth12.1dpristane (150 ul) 69784pristane (150 ul)
18post-insult time to onset of experimental arthritisPVG.1AV1both38dpristane (150 ul) 69785pristane (150 ul)
16post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-D4Rat84)both13.1dpristane (150 ul) 69786pristane (150 ul)
24post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat155-Spr)both12.5dpristane (150 ul) 69787pristane (150 ul)
9post-insult time to onset of experimental arthritisDA/Ztmboth14dsqualene (200 ul) 69788squalene (200 ul)
10post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat63-D4Rat203)both16.9dsqualene (200 ul) 69789squalene (200 ul)
10post-insult time to onset of experimental arthritisDA/Ztmboth14.2dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69790type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
10post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat63-D4Rat203)both16.4dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69791type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
10post-insult time to onset of experimental arthritisDA/Ztmboth14.2dpristane (150 ul) 69792pristane (150 ul)
10post-insult time to onset of experimental arthritisDA.PVG.1AV1-(D4Rat63-D4Rat203)both15.5dpristane (150 ul) 69793pristane (150 ul)
9post-insult time to onset of experimental arthritisDA/Ztmmale15.2dtype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69782type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
29percentage of study population developing experimental arthritis during a period of timeDXE3/Ztmboth3%pristane (150 ul) (for 110 days)70142pristane (150 ul) (for 110 days)
1post-insult time to onset of experimental arthritisDXE3/Ztmboth43dpristane (150 ul) (for 110 days)70145pristane (150 ul) (for 110 days)
15percentage of study population developing experimental arthritis during a period of timeDA/Bklmale100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70146type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
14percentage of study population developing experimental arthritis during a period of timeDA/Bklfemale100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70147type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
10percentage of study population developing experimental arthritis during a period of timeF344/NHsdmale20%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70148type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
10percentage of study population developing experimental arthritis during a period of timeF344/NHsdfemale30%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70149type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
10percentage of study population developing experimental arthritis during a period of timeDA.F344-(D10Arb20-D10Arb22)/Arbmale100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70152type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
10percentage of study population developing experimental arthritis during a period of timeDA.F344-(D10Arb20-D10Arb22)/Arbfemale100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70153type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
9percentage of study population developing experimental arthritis during a period of timeDA.F344-(D10Rat204-D10Arb22)/Arbmale100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70154type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
10percentage of study population developing experimental arthritis during a period of timeDA.F344-(D10Rat204-D10Arb22)/Arbfemale100%type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) 70155type II collagen (2 mg/kg) Freund's incomplete adjuvant (50 %)
14percentage of study population developing experimental arthritis during a period of timeLEW.1Fmale86%pristane (150 ul) 69813pristane (150 ul)
8percentage of study population developing experimental arthritis during a period of timeLEW.1Ffemale100%pristane (150 ul) 69814pristane (150 ul)
5percentage of study population developing experimental arthritis during a period of timeE3male0%pristane (150 ul) 69815pristane (150 ul)
5percentage of study population developing experimental arthritis during a period of timeE3female0%pristane (150 ul) 69816pristane (150 ul)
14post-insult time to onset of experimental arthritisLEW.1Fmale31dpristane (150 ul) 69817pristane (150 ul)
8post-insult time to onset of experimental arthritisLEW.1Ffemale18dpristane (150 ul) 69818pristane (150 ul)
104percentage of study population developing experimental arthritis during a period of timeDA/ZtmRhdboth100%pristane (150 ul) 69838pristane (150 ul)
10percentage of study population developing experimental arthritis during a period of timeE3/ZtmRhdboth0%pristane (150 ul) 69839pristane (150 ul)
104arthritic paw countDA/ZtmRhdboth3.3pristane (150 ul) 69840pristane (150 ul)
10arthritic paw countE3/ZtmRhdboth0pristane (150 ul) 69841pristane (150 ul)
104post-insult time to onset of experimental arthritisDA/ZtmRhdboth12dpristane (150 ul) 69842pristane (150 ul)
11percentage of study population developing chronic experimental arthritis during a period of timeBBDR/Rhwmale100%Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days)69921Freund's incomplete adjuvant (50 %) (between 1 and 7 days)type II collagen (2 mg/kg) (between 1 and 7 days)Freund's incomplete adjuvant (50 %) (between 1 and 35 days)type II collagen (100 ug) (between 1 and 35 days)
13percentage of study population developing chronic experimental arthritis during a period of timeBBDR/Rhwfemale100%Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days)69922Freund's incomplete adjuvant (50 %) (between 1 and 7 days)type II collagen (2 mg/kg) (between 1 and 7 days)Freund's incomplete adjuvant (50 %) (between 1 and 35 days)type II collagen (100 ug) (between 1 and 35 days)
13percentage of study population developing chronic experimental arthritis during a period of timeBN/SsNmale0%Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days)69923Freund's incomplete adjuvant (50 %) (between 1 and 7 days)type II collagen (2 mg/kg) (between 1 and 7 days)Freund's incomplete adjuvant (50 %) (between 1 and 35 days)type II collagen (100 ug) (between 1 and 35 days)
7percentage of study population developing chronic experimental arthritis during a period of timeBN/SsNfemale0%Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days)69924Freund's incomplete adjuvant (50 %) (between 1 and 7 days)type II collagen (2 mg/kg) (between 1 and 7 days)Freund's incomplete adjuvant (50 %) (between 1 and 35 days)type II collagen (100 ug) (between 1 and 35 days)
4percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified100%Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (5 mg) then cyclophosphamide (8 mg) 110793Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml) cyclophosphamide (5 mg) cyclophosphamide (8 mg)
3percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified100%Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110794Freund's complete adjuvant (0.05-0.1 ml) Hu-S102-129 (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
4percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified100%Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110795Freund's complete adjuvant (0.05-0.1 ml) Hu-S110-129 (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
5post-insult time to onset of experimental autoimmune encephalomyelitisLOU/Mnot specified11dFreund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110796Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
4post-insult time to onset of experimental autoimmune encephalomyelitisLOU/Mnot specified11dFreund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) 110797Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml) cyclophosphamide (8 mg) cyclophosphamide (5 mg)
3post-insult time to onset of experimental autoimmune encephalomyelitisLOU/Mnot specified11dFreund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110798Freund's complete adjuvant (0.05-0.1 ml) Hu-S102-129 (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
4post-insult time to onset of experimental autoimmune encephalomyelitisLOU/Mnot specified11dFreund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110799Freund's complete adjuvant (0.05-0.1 ml) Hu-S110-129 (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
5experimental autoimmune encephalomyelitis durationLOU/Mnot specified8dFreund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110800Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
4experimental autoimmune encephalomyelitis durationLOU/Mnot specified11dFreund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) 110801Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml) cyclophosphamide (8 mg) cyclophosphamide (5 mg)
4experimental autoimmune encephalomyelitis durationLOU/Mnot specified8dFreund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110803Freund's complete adjuvant (0.05-0.1 ml) Hu-S110-129 (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
3post-insult time to onset of experimental autoimmune encephalomyelitisLOU/Mnot specified5drat anti-Hu-S102-129 T cell line (9 x 10E6 cells) 110782rat anti-Hu-S102-129 T cell line (9 x 10E6 cells)
9percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified100%rat anti-Hu-MBP T cell line (9 x 10E6 cells) 110780rat anti-Hu-MBP T cell line (9 x 10E6 cells)
3experimental autoimmune encephalomyelitis durationLOU/Mnot specified8drat anti-Hu-S102-129 T cell line (9 x 10E6 cells) 110789rat anti-Hu-S102-129 T cell line (9 x 10E6 cells)
4percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified0%Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) 110790Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml)
4percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified0%Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) 110791Freund's complete adjuvant (0.05-0.1 ml) Hu-S110-129 (0.05-0.1 ml)
5percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified100%Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110792Freund's complete adjuvant (0.05-0.1 ml) human myelin basic protein (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
3experimental autoimmune encephalomyelitis durationLOU/Mnot specified8dFreund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) 110802Freund's complete adjuvant (0.05-0.1 ml) Hu-S102-129 (0.05-0.1 ml) pertussis toxin (3.5 ug) pertussis toxin (3.5 ug)
3percentage of study population developing experimental autoimmune encephalomyelitis during a period of timeLOU/Mnot specified100%rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) 110781rat anti-Hu-S102-129 T cell line (9 x 10E6 cells)
9post-insult time to onset of experimental autoimmune encephalomyelitisLOU/Mnot specified6drat anti-Hu-MBP T cell line (9 x 10E6 cells) 110783rat anti-Hu-MBP T cell line (9 x 10E6 cells)
9experimental autoimmune encephalomyelitis durationLOU/Mnot specified6drat anti-Hu-MBP T cell line (9 x 10E6 cells) 110784rat anti-Hu-MBP T cell line (9 x 10E6 cells)
5litter sizeISIAHfemale8.6control condition110669control condition
5litter sizeWAG/Novfemale7.6control condition110670control condition
16ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale19%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days)111146DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)sodium chloride solution (2 ml) (for 7 days)sodium chloride solution (2 ml) (for 7 days)
18ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale39%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days)111147DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)5-fluorouracil (100 mg/kg) (for 7 days)
18ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale44%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111148DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
21ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale81%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111149DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
16ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale0%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days)111150DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)sodium chloride solution (2 ml) (for 7 days)sodium chloride solution (2 ml) (for 7 days)
18ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale0%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days)111151DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)5-fluorouracil (100 mg/kg) (for 7 days)
18ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale0%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111152DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
21ratio of survivors to total study population during a period of timeBDIX/OrlCrlmale9.5%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111153DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
N/Alitter sizeSah:SDfemale10.2control condition111383control condition
3litter sizeSD-Cftrem1Apbfemale9.8control condition110764control condition
N/Alitter sizeSD-Cftrem2Apbfemale11.7control condition110765control condition
N/Aratio of survivors of meconium ileus to total study population during a period of timeSD-Cftrem1Apbnot specified84%control condition111459control condition
N/Aratio of survivors of meconium ileus to total study population during a period of timeSD-Cftrem2Apbnot specified60%controlled ColonLYTELY content drinking water (4.5 %) (for 7 days)111460controlled ColonLYTELY content drinking water (4.5 %) (for 7 days)
N/Aratio of survivors of meconium ileus to total study population during a period of timeSD-Cftrem2Apbnot specified34%controlled ColonLYTELY content drinking water (4.5 %) (for 60 days)111462controlled ColonLYTELY content drinking water (4.5 %) (for 60 days)
N/Aratio of survivors of meconium ileus to total study population during a period of timeSD-Cftrem1Apbnot specified66%control condition111461control condition